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Abstract
Purpose To perform a genotype–phenotype
correlation for three patients heterozygous for
a missense mutation in the tissue inhibitor of
metalloproteinase 3 (TIMP3) gene.
Methods Retrospective, observational case
series. The medical records and photographs
were reviewed for three patients diagnosed at
the time with neovascular age-related macular
degeneration (AMD). All were later found to
carry a predicted C113G mutation in the TIMP3
gene, other known mutations in which are
associated with Sorsby’s fundus dystrophy.
Results All three patients developed drusen
and bilateral choroidal neovascularisation with
subsequent disciform scarring and atrophy.
Visual acuity rapidly deteriorated to o6/60 in
both eyes. The age of onset varied from 56 to 64
years and the interval to contralateral eye
involvement varied from 4 to 6 years. Two of the
three patients had a family history of AMD. All
three patients were heterozygous for the C113G
nucleotide change, resulting in a Ser38Cys
change at the N terminus of the TIMP3 protein.
Conclusion This case series suggests the
C113G TIMP3 variant may represent a novel
highly penetrant mutation causing choroidal
neovascularisation of relatively late onset for
Sorsby’s fundus dystrophy, mimicking early
onset AMD.
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Introduction
Age-related macular degeneration (AMD) is the
commonest cause of blindness in the developed
world.1 Genetic predisposition is thought to play
a role and to date 19 genetic loci have been
associated at a genome-wide level with an
increased risk of developing AMD.2
Sorsby’s fundus dystrophy (SFD) is a rare
autosomal dominant fundus dystrophy caused
by mutations in the tissue inhibitor of
metalloproteinase 3 (TIMP3) gene.3 It shares
similar clinical features with AMD, including
choroidal neovascularisation (CNV), although
the age of onset is typically younger in the fourth
decade of life.
We report the clinical phenotypes of three
patients diagnosed at Southampton Eye Unit
with bilateral neovascular AMD before the
availability of anti-vascular endothelial growth
factor (VEGF) therapies. All three were later
found to be heterozygous for a predicted
mutation, C113G, in the TIMP3 gene. These
genotypes were identiﬁed through a




A 56-year-old man presented with recent
deterioration of vision in his left eye. Visual
acuity was 6/9 in the right eye and 3/60 in the
left eye. Examination revealed haemorrhage and
subretinal ﬂuid at the left macula. He had a
family history of ‘macular degeneration’.
He then returned to the eye unit 4 years later
with ‘advanced macular degeneration’ in the
right eye. Visual acuity was now 2/60 in the
right eye and hand movements in the left eye
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Case 2
A 64-year old man presented with sudden-onset reduced
vision in his left eye. Visual acuity was 6/6 in the right eye
and counting ﬁngers in the left. Fluorescein angiography
revealed a left subfoveal classic CNV. Both his grandmother
and uncle had also been diagnosed with AMD.
Five years later his vision had decreased to 6/36 in the
right eye. Fundus examination showed bilateral drusen
with macular haemorrhage in the right eye and a left
disciform scar (Figure 1a and b). Fluorescein angiography
revealed a peripapillary CNV (Figure 1c and d). This was
treated with radiotherapy, however by the following year
his vision had decreased further to 6/60.
Case 3
A 61-year old woman developed choroidal
neovascularisation in her left eye, reducing her vision to
hand movements. She had no family history of AMD. Six
years later she developed symptoms in her right eye.
Examination revealed bilateral drusen, disciform scarring
in the left eye and haemorrhage at the right macula
(Figure 2a and b). Indocyanine green angiography
ﬁndings suggested right polypoidal choroidopathy
(Figure 2c and d). Despite treatment with photodynamic
therapy her visual acuity deteriorated from 6/36 to hand
movements a year later.
Discussion
TIMP3 is a 24 kD protein that inhibits matrix
metalloproteinases. It is secreted by the retinal pigment
epithelium (RPE) and deposits in Bruch’s membrane
where it regulates extracellular matrix turnover,5 inhibits
angiogenesis6 and regulates inﬂammation.7 Eleven
distinct mutations to date have been associated with
Sorsby's fundus dystrophy. All of these create unpaired
cysteine residues in the C-terminal domain of the TIMP3
protein.8 This results in the formation of dimers which
accumulate in Bruch’s membrane, compromising
extracellular matrix turnover.9 RPE function is
subsequently affected, leading to RPE atrophy and CNV.
The three patients described, diagnosed at the time with
bilateral ‘neovascular AMD’, were found to be heterozygous
for a predicted mutation, C113G, causing a Ser38Cys change
and unpaired cysteine residue in the N terminus of TIMP3.
The only other published report of this mutation describes
two patients with strong family histories of early onset
Figure 1 Fundus photographs of patient 2 taken at the onset of right eye visual symptoms. Haemorrhage at the right macula (a),
disciform scarring in the left eye (b) and bilateral drusen are shown. Early (c) and late (d) ﬂuorescein angiography in the right eye
revealed peripapillary choroidal neovascularisation.
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AMD who developed bilateral recurrent choroidal
neovascularisation in their forties.8 By contrast, our three
patients developed visual symptoms between 56 and 64
years, and one patient had no family history of AMD.
Recently presented work from the IAMDGC identiﬁed 28
heterozygotes for rare TIMP3mutations and variants within
16 144 advanced AMD cases versus one heterozygote
among 420 000 controls, which includes our three cases.4
The majority of these carried the C113G mutation and the
average age of onset for macular disease was 65 years. This
was signiﬁcantly earlier than for non-carriers (77 years old,
Po0.000001) but older than is typical for SFD.
We therefore conclude that the C113G TIMP3 mutation
phenotype may mimic early onset neovascular AMD. Our
report represents the ﬁrst genotype–phenotype
correlation of this mutation emerging from the IAMDGC.
Cascade genetic testing for this rare highly penetrant
allele in the relatives of patients with CNV diagnosed as
early onset AMD may identify asymptomatic carriers
who require close monitoring for future development of
macular disease. This would aid prompt initiation of anti-
VEGF therapy to prevent sight loss.10
Summary
What was known before
K A number of genetic variants have been associated
with increased risk of developing age-related macular
degeneration (AMD).
K Sorsby's fundus dystrophy (SFD) is a rare autosomal dominant
fundus dystrophy caused by mutations in the TIMP3 gene.
K SFD shares certain clinical features with AMD, however
the age of onset is typically younger.
What this study adds
K We report a genotype–phenotype correlation for three
patients diagnosed at the time with early onset
neovascular AMD, who were later found to carry
a 'predicted' mutation in the TIMP3 gene (C113G).
K Our report represents the ﬁrst genotype–phenotype
correlation of this mutation emerging from the
International AMD Genomics Consortium.
K We conclude that the C113G TIMP3 mutation may
represent a novel highly penetrant mutation causing
choroidal neovascularisation of relatively late onset for
Sorsby's fundus dystrophy, mimicking early onset AMD.
Cascade genetic testing in the relatives of affected patient
may identify asymptomatic carriers who require close
monitoring for future development of macular disease.
Figure 2 Fundus photographs of patient 3 taken at the onset of right eye visual symptoms, showing bilateral drusen, right eye macular
haemorrhage (a) and a left disciform scar (b). Early (c) and late (d) indocyanine green angiography suggested polypoidal choroidopathy
temporal to the right optic disc.
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